Biotech RadarJobs updated

COMPANY

Azitra Inc.

HQ: Branford, CT source · azitrainc.com ↗ · New England

Clinical Phase 2

Azitra is a clinical-stage biopharmaceutical company focused on precision dermatology, using engineered proteins and live biotherapeutic products. From company website Source · checked 2026-10-19

Sources for this description (1)
  • Azitra is a clinical-stage biopharmaceutical company focused on precision dermatology, using engineered proteins and live biotherapeutic products.
    • “We are a clinical-stage biopharmaceutical company focused on precision dermatology, using engineered proteins and live biotherapeutic products.” https://azitrainc.com/about-us/ (2026-10-19)

Keywords: dermatology skin disease Netherton Syndrome EGFR Inhibitor-associated Rash Epidermal Growth Factor Papulopustular Rosacea Study of Three Doses of AZT-04 for Skin Appearance ATR12-351 ATR04-484 ATR-04

Location: Branford, CT · source · Oct 15, 2026

Profile checked Oct 10, 2026

$14.4MRaised (2 yrs)4Trials (company is sponsor)2NIH grants

Timeline

  1. Raise Private placement: $10.5M (initial closing, as published); deal value up to $20.9M (not counted as received), announced Mar 19, 2026. Source: SEC filing. source ↗
  2. Raise Private placement: $1.5M (total, as published), announced Nov 24, 2025. Source: SEC filing. source ↗
  3. Trial start Phase 1/Phase 2: A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity source ↗
  4. Raise Follow-on offering — Registered direct: $930,000 (total, as published), announced Feb 4, 2025. Source: SEC filing. source ↗
  5. Raise Follow-on offering: $1.5M (total, as published), announced Jan 15, 2025. Source: SEC filing. source ↗
  6. Trial start Phase 1: Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome source ↗
  7. Trial start Phase 1/Phase 2: Study to Evaluate the Safety of ATR-04 source ↗
  8. Trial start Not phased (device or behavioral study): Safety Study of AZT-04 for Cosmetic Use source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $14.4M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT06137157Evaluation of Topical ATR12-351 in Adults With Netherton SyndromePhase 1CompletedJun 16, 2024Jul 7, 2026 (actual)
NCT06830863A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal ToxicityPhase 1/Phase 2RecruitingAug 25, 2025Jan 15, 2027 (estimated)
NCT04731259Study to Evaluate the Safety of ATR-04Phase 1/Phase 2Withdrawn2024-012026-01 (estimated)
NCT03820076Safety Study of AZT-04 for Cosmetic UseNot phased (device or behavioral study)CompletedJan 17, 2019Jan 21, 2019 (actual)

NIH awards 2

Annual award amounts. Total $375K.

Feedback